Please try another search
Portola Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in Europe and the United States. It produces Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya brand; Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness; cerdulatinib, an investigational oral, dual spleen tyrosine kinase; and Janus kinases inhibitor for the treatment of hematologic cancers. The company was incorporated in 2003 and is based in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review